MAKO Surgical Corp. Files for $86.3 Million IPO
Published: Sep 19, 2007
FT. LAUDERDALE, Fla., Sept. 19 /PRNewswire-FirstCall/ -- MAKO Surgical Corp. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock.
All of the offered shares will be sold by MAKO Surgical Corp. The number of shares to be offered and the price range of the offering have not yet been determined. The Company intends to apply to have its common stock approved for quotation on the NASDAQ Global Market under the symbol "MAKO."
J.P. Morgan Securities Inc. and Morgan Stanley & Co. Incorporated will act as joint bookrunners for the offering and Cowen and Company, LLC and Wachovia Capital Markets, LLC will act as co-lead managers. The offering will be made only by means of a prospectus. Copies of the preliminary prospectus for the offering, when available, may be obtained from: J.P. Morgan Securities Inc., National Statement Processing, Prospectus Library, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245 or by phone at (718) 242-8002; or Morgan Stanley & Co. Incorporated's prospectus department at 180 Varick, New York, NY 10014, by telephone at (866) 718-1649 or by emailing email@example.com.
About MAKO Surgical Corp.
MAKO Surgical Corp. is a medical device company that markets its advanced robotic solution and implants for minimally invasive orthopedic knee procedures. MAKO's Haptic Guidance System(TM) includes an interactive haptic robotics platform that utilizes tactile-guided robotics and patient-specific visualization to prepare the knee joint for the insertion and alignment of resurfacing implants through a keyhole incision. This FDA-cleared surgeon- interactive haptic robotic system allows surgeons to provide an innovative tissue-sparing bone resurfacing therapy called MAKOplasty(TM) to a large, yet underserved patient-specific population suffering from early to mid-stage osteoarthritic knee disease. As of September 18, 2007, 80 MAKOplasty procedures have been performed since commercial introduction in June 2006. MAKO has an intellectual property portfolio of more than two hundred licensed or owned patent applications relating to the areas of computer assisted surgery, haptics, robotics, and implants.
A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.MAKO Surgical Corp.
CONTACT: Susan M. Verde of MAKO Surgical Corp., +1-954-927-2044, x349,firstname.lastname@example.org